Arcus Biosciences (RCUS) Free Cash Flow Growth (3y) (2020 - 2026)
Arcus Biosciences (RCUS) Free Cash Flow Growth (3y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,200.25 Bn | 66,199.96 Bn | - | -5.05% |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 471.75 Bn | 466.96 Bn | 1.35 Bn | 31.07% |
| 5 | Vertex Pharmaceuticals | 121.94 Bn | 114.69 Bn | 2.59 Bn | 14.71% |
| 6 | Regeneron Pharmaceuticals | 69.87 Bn | 61.12 Bn | 3.31 Bn | -10.65% |
| 7 | Belite Bio | 62.43 Bn | 62.43 Bn | - | - |
| 8 | Argenx Se | 55.86 Bn | 50.68 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | 31.42% |
| 10 | Arcus Biosciences | 3.53 Bn | 2.71 Bn | - | -9.19% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.19% |
| Dec 31, 2025 | -18.89% |
| Sep 30, 2025 | -4.91% |
| Jun 30, 2025 | -28.28% |
| Mar 31, 2025 | -30.14% |
| Dec 31, 2024 | -15.93% |
| Sep 30, 2024 | 40.64% |
| Jun 30, 2024 | -11.10% |
| Mar 31, 2024 | 64.85% |
| Dec 31, 2023 | -24.61% |
| Sep 30, 2023 | -32.22% |
| Jun 30, 2023 | -33.67% |
| Mar 31, 2023 | -49.88% |
| Dec 31, 2022 | -95.29% |
| Sep 30, 2022 | -44.31% |
| Jun 30, 2022 | -45.27% |
| Mar 31, 2022 | 241.44% |
| Dec 31, 2021 | -152.26% |
| Sep 30, 2021 | -60.45% |
| Jun 30, 2021 | -84.91% |